

DOCUMENTS FILED AS PART OF THIS FORM 6-K

See the Exhibit Index hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Tekmira Pharmaceuticals Corporation

Date: June 27, 2012

By: /s/ IAN C. MORTIMER

Name: Ian C. Mortimer

Title: *Executive Vice President, Finance and Chief Financial Officer*

EXHIBIT INDEX

| Exhibit | Description |
|----------------|--------------------------|
| 99.1 | Report of Voting Results |

**ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
OF
TEKMIRA PHARMACEUTICALS CORPORATION
(THE "COMPANY") HELD ON JUNE 20, 2012**

REPORT OF VOTING RESULTS

National Instrument 51-102 – Continuous Disclosure Obligations (Section 11.3)

The following matters were put to a vote by a show of hands at the annual and special meeting of the Company:

| | Outcome of Vote |
|---|------------------------|
| 1. The election of the following nominees as directors of the Company for the ensuing year or until their successors are elected or appointed: Michael Abrams Kenneth Galbraith Don Jewell Frank Karbe Daniel Kisner Mark J. Murray | Carried |
| 2. The appointment of KPMG LLP as auditor of the Company for the ensuing year. | Carried |
| 3. Resolution of shareholders of the Company approving the amendment to the Company's omnibus share compensation plan to increase from 1,643,144 to 2,193,870 common shares in respect of which awards may be granted thereunder. | Carried |

DATED the 22nd day of June, 2012.

TEKMIRA PHARMACEUTICALS CORPORATION

By: /s/ R. Hector MacKay-Dunn
R. Hector MacKay-Dunn, Q.C.
Corporate Secretary